Open clinical trials in mainland China
4,406 open trials registered on ClinicalTrials.gov with at least one of 401 hospitals on this site as lead sponsor or study site, as registered on 8 Nov 2026. Newest posted first; filter by disease, date posted, the registered age and sex, phase and city.
Not a ranking or a recommendation. Whether someone can take part is decided by the study team. Trials registered only in China’s own registry (ChiCTR) are not included.
Trials
4,406 trials
Recruiting
Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) InjectionLung cancer
Led by Tongji Hospital. . Start date 2025-04. NCT07947043
- Phase
- Phase 1
- Ages
- 18–75
- Where
- Wuhan
118–75Wuhan1 listed hospitalNot yet recruiting
Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung Cancer.Lung cancer
Led by Quanzhou First Hospital, Fujian Medical University. . Start date 2027-01. NCT07944313
- Phase
- Phase 2
- Ages
- 60–90
- Where
- Quanzhou
260–90Quanzhou1 listed hospitalNot yet recruiting
Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor FailureLymphoma
Led by Tianjin Medical University Cancer Institute & Hospital. . Start date 2026-12. NCT07944651
- Phase
- Phase 2
- Ages
- 18 and over
- Where
- Tianjin
218 and overTianjin1 listed hospitalNot yet recruiting
Function-Friendly Semi-Fowler Positioning for Coronary Angiography and PCICoronary heart disease
Led by Zhongshan Hospital, Fudan University. . Start date 2026-11. NCT07944716
- Phase
- Not stated
- Ages
- 18–75
- Where
- Shanghai
Not stated18–75Shanghai1 listed hospitalNot yet recruiting
Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT LymphomaLymphoma
Led by Fudan University Shanghai Cancer Center. . Start date 2026-11. NCT07945353
- Phase
- Phase 2
- Ages
- 18 and over
- Where
- Shanghai
218 and overShanghai1 listed hospitalRecruiting
Multimodal Ultrasound for Lymphoma Classification and Treatment Response PredictionLymphoma
Led by Chinese PLA General Hospital. . Start date 2026-01. NCT07941063
- Phase
- Not stated
- Ages
- 18 and over
- Where
- Beijing
Not stated18 and overBeijing1 listed hospitalRecruiting
Pragmatic AI-Assisted Lung Cancer Translational StudyLung cancer
Led by Sir Run Run Shaw Hospital; 1 listed hospital as study site. . Start date 2026-08. NCT07941128
- Phase
- Not stated
- Ages
- 18 and over
- Where
- Hangzhou, Zhengzhou
Not stated18 and overHangzhou, Zhengzhou2 listed hospitalsNot yet recruiting
Study on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer PatientsBreast cancer
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine. . Start date 2026-10. NCT07942103
- Phase
- Not stated
- Ages
- 18–70, women only
- Where
- Tianjin
Not stated18–70Women onlyTianjin1 listed hospitalNot yet recruiting
Multimodal LLM for Breast Cancer Radiotherapy Target Auto-Contouring and PlanningBreast cancer
Led by Sun Yat-sen Memorial Hospital. . Start date 2026-11. NCT07943494
- Phase
- Not stated
- Ages
- Not stated
- Where
- Guangzhou
Not statedNot statedGuangzhou1 listed hospitalRecruiting
Prospective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular ClassificationGlioma
Led by Beijing Tiantan Hospital. . Start date 2026-07. NCT07940231
- Phase
- Not stated
- Ages
- 18 and over
- Where
- Beijing
Not stated18 and overBeijing1 listed hospitalNot yet recruiting
Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaLymphoma
Lead sponsor is not a listed hospital; 1 listed hospital as study site. . Start date 2026-12. NCT07938619
- Phase
- Phase 2
- Ages
- 18 and over
- Where
- Guangzhou
218 and overGuangzhou1 listed hospitalRecruiting
Cardiopulmonary Exercise Active Health Cohort StudyCoronary heart disease
Led by Peking University Third Hospital. . Start date 2026-05. NCT07935187
- Phase
- Not stated
- Ages
- 18–80
- Where
- Beijing
Not stated18–80Beijing1 listed hospitalRecruiting
Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)Lymphoma
Led by Tongji Hospital. . Start date 2025-10. NCT07934537
- Phase
- Phase 4
- Ages
- 18–70
- Where
- Shanghai
418–70Shanghai1 listed hospitalNot yet recruiting
Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung CancerLung cancer
Led by Affiliated Cancer Hospital of Guizhou Medical University. . Start date 2026-10. NCT07936578
- Phase
- Phase 2
- Ages
- 18–75
- Where
- Guiyang
218–75Guiyang1 listed hospitalRecruiting
Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer PatientsBreast cancer
Led by First Affiliated Hospital of Guangxi Medical University. . Start date 2026-11. NCT07933653
- Phase
- Not stated
- Ages
- 18–70, women only
- Where
- Nanning
Not stated18–70Women onlyNanning1 listed hospitalRecruiting
Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical SignificancePancreatic cancer
Led by Second Affiliated Hospital of Nanjing Medical University. . Start date 2026-10. NCT07933952
- Phase
- Not stated
- Ages
- 18–80
- Where
- Nanjing
Not stated18–80Nanjing1 listed hospitalNot yet recruiting
AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRPCoronary heart disease
Led by Union Hospital. . Start date 2026-11. NCT07933757
- Phase
- Not stated
- Ages
- 18 and over
- Where
- Wuhan
Not stated18 and overWuhan1 listed hospitalRecruiting
A Phase I Clinical Study of YN003 in the Treatment of GliomaGlioma
Lead sponsor is not a listed hospital; 2 listed hospitals as study sites. . Start date 2026-10. NCT07929909
- Phase
- Phase 1
- Ages
- 18–70
- Where
- Beijing
118–70Beijing2 listed hospitalsNot yet recruiting
Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung CancerLung cancer
Led by National Cancer Center / Cancer Hospital, CAMS. . Start date 2027-01. NCT07928882
- Phase
- Not stated
- Ages
- 18 and over
- Where
- Beijing
Not stated18 and overBeijing1 listed hospitalNot yet recruiting
A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic CancerPancreatic cancer
Led by Ruijin Hospital; 4 listed hospitals as study sites. . Start date 2026-10. NCT07928362
- Phase
- Not stated
- Ages
- 18–75
- Where
- Chengdu, Qingdao +2
Not stated18–75Chengdu, Qingdao +25 listed hospitalsRecruiting
Artificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic Cancer LesionsPancreatic cancer
Led by Ruijin Hospital. . Start date 2024-11. NCT07925125
- Phase
- Not stated
- Ages
- 18–75
- Where
- Shanghai
Not stated18–75Shanghai1 listed hospitalRecruiting
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsStomach cancerBreast cancer
Lead sponsor is not a listed hospital; 3 listed hospitals as study sites. . Start date 2024-07. NCT07923214
- Phase
- Phase 1
- Ages
- 18 and over
- Where
- Chengdu, Fuzhou +1
118 and overChengdu, Fuzhou +13 listed hospitalsNot yet recruiting
GK01 Cell Therapy in Gastric Cancer With Peritoneal MetastasisStomach cancer
Led by Ruijin Hospital. . Start date 2026-11. NCT07923396
- Phase
- Phase 1
- Ages
- 18 and over
- Where
- Shanghai
118 and overShanghai1 listed hospitalEnrolling by invitation
Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid TumorsLung cancer
Lead sponsor is not a listed hospital; 1 listed hospital as study site. . Start date 2026-01. NCT07920822
- Phase
- Phase 1
- Ages
- 18–75
- Where
- Wuhan
118–75Wuhan1 listed hospitalRecruiting
Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction AdenocarcinomaStomach cancer
Led by Union Hospital. . Start date 2025-07. NCT07920224
- Phase
- Phase 2
- Ages
- 18–75
- Where
- Wuhan
218–75Wuhan1 listed hospitalRecruiting
Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving SurgeryBreast cancer
Led by Sir Run Run Shaw Hospital; 10 listed hospitals as study sites. . Start date 2023-07. NCT07920094
- Phase
- Not stated
- Ages
- 18–70, women only
- Where
- Hangzhou, Jinhua +3
Not stated18–70Women onlyHangzhou, Jinhua +311 listed hospitalsNot yet recruiting
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia GravisMyasthenia gravis
Led by Tongji Hospital. . Start date 2026-12. NCT07917923
- Phase
- Early phase 1
- Ages
- 18–65
- Where
- Wuhan
Early phase 118–65Wuhan1 listed hospitalNot yet recruiting
Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic FeaturesNasopharyngeal carcinoma
Led by Zhongshan City People's Hospital; 1 listed hospital as study site. . Start date 2026-11. NCT07918755
- Phase
- Not stated
- Ages
- 18 and over
- Where
- Nanning, Zhongshan
Not stated18 and overNanning, Zhongshan2 listed hospitalsNot yet recruiting
Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABGCoronary heart disease
Lead sponsor is not a listed hospital; 4 listed hospitals as study sites. . Start date 2026-12. NCT07918781
- Phase
- Not stated
- Ages
- 18 and over
- Where
- Beijing, Changsha +2
Not stated18 and overBeijing, Changsha +24 listed hospitalsNot yet recruiting
Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCTB-cell acute lymphoblastic leukaemia
Led by Peking University People's Hospital; 1 listed hospital as study site. . Start date 2026-11. NCT07919470
- Phase
- Not stated
- Ages
- 14–65
- Where
- Beijing, Langfang
Not stated14–65Beijing, Langfang2 listed hospitals
“Posted” is when the study first appeared on ClinicalTrials.gov; “updated” is its latest change there. Ages and sex are the registered criteria, not a check of who can join. The order is not a ranking.